Because depletion of UXS1 increased the levels of UDP-GlcA in UGDH-deficient hepatocytes and suppressed TNFα-induced RIPK1 activation and apoptosis, we next tested the potential of UXS1 as a therapeutic target in NASH. The gene discussed is RIPK1; the disease is metabolic dysfunction-associated steatohepatitis.